Trip Answers

Question answered:11/08/06 Warning! this question is over two years old.

We found very little ‘solid’ evidence to answer this question. 

GP Notebook has a section on dystonia [1]. However, this only gives management advice in the case of dystonia due to phenothiazines. 

Cochrane have produced a number of systematic reviews on dystonia [2, 3, 4] but these are for cervical dystonia.

The American National Institute of Neurological Disorders and Stroke has a section on dystonia [5].  This seems to suggest that the type of dystonia is oromandibular dystonia, stating:

“Oromandibular dystonia affects the muscles of the jaw, lips, and tongue. The jaw may be pulled either open or shut, and speech and swallowing can be difficult.” 

This further discusses treatments (for dystonia, not specifically oromandibular) reporting:

“No one treatment has been found universally effective. Instead, physicians use a variety of therapies aimed at reducing or eliminating muscle spasms and pain.

Medication. Several classes of drugs that may help correct imbalances in neurotransmitters have been found useful. But response to drugs varies among patients and even in the same person over time. The most effective therapy is often individualized, with physicians prescribing several types of drugs at different doses to treat symptoms and produce the fewest side effects. Note that not all of the medications mentioned below are currently available for patients in the United States.

Frequently, the first drug administered belongs to a group that reduces the level of the neurotransmitter acetylcholine. Drugs in this group include trihexyphenidyl, benztropine, and procyclidine HCl. Sometimes these medications can be sedating, especially at higher doses, and this can limit their usefulness.

Drugs that regulate the neurotransmitter GABA may be used in combination with these drugs or alone in patients with mild symptoms. GABA-regulating drugs include the muscle relaxants diazepam, lorazepam, clonazepam, and baclofen.

Other drugs act on dopamine, a neurotransmitter that helps the brain fine-tune muscle movement. Some drugs which increase dopamine effects include levodopa/carbidopa and bromocriptine. DRD has been remarkably responsive to small doses of this dopamine-boosting treatment. On the other hand, patients have occasionally benefited from drugs that decrease dopamine, such as reserpine or the investigational drug tetrabenazine. Once again, side effects can restrict the use of these medications.

Anticonvulsants including carbamazepine, usually prescribed to control epilepsy, have occasionally helped individuals with dystonia.

Botulinum toxin. Minute amounts of this familiar toxin can be injected into affected muscles to provide temporary relief of focal dystonias. First used to treat blepharospasm, such injections have gained wider acceptance among physicians for treating other focal dystonias. The toxin stops muscle spasms by blocking release of the excitatory neurotransmitter acetylcholine. The effect lasts for up to several months before the injections have to be repeated.

Surgery and other treatments. Surgery may be recommended for some patients when medication is unsuccessful or the side effects are too severe. In selected cases, advanced generalized dystonias have been helped, at least temporarily, by surgical destruction of parts of the thalamus, a structure deep in the brain that helps control movement. Speech disturbance is a special risk accompanying this procedure, since the thalamus lies near brain structures that help control speech. Surgically cutting or removing the nerves to the affected muscles has helped some focal dystonias, including blepharospasm, spasmodic dysphonia and torticollis. The benefits of these operations, however, can be short-lived. They also carry the risk of disfigurement, can be unpredictable, and are irreversible.

Some patients with spasmodic dysphonia may benefit from treatment by a speech-language pathologist. Physical therapy, splinting, stress management, and biofeedback may also help individuals with certain forms of dystonia.”

There appears to be a UK charity ‘The Dystonia Society’ which has a section on oromandibular dystonia [6], this may be of some interest.

References

1) http://www.gpnotebook.co.uk/simplepage.cfm?ID=926220288
2) Cochrane Collaboration. Botulinum toxin type A versus anticholinergics for cervical dystonia (http://www.cochrane.org/reviews/en/ab004312.html)
3) Cochrane Collaboration. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia (http://www.cochrane.org/reviews/en/ab004314.html)
4) Cochrane Collaboration. Botulinum toxin type A versus anticholinergics for cervical dystonia. (http://www.cochrane.org/reviews/en/ab004312.html)
5) http://www.ninds.nih.gov/disorders/dystonias/detail_dystonias.htm
6) http://www.dystonia.org.uk/about-dystonia-page7540.html

---

DISCLAIMER: TRIPanswers is a collection of clinical questions and answers.  Each provider will have their own methodology in answering questions and these are likely not to be as rigorous as systematic review.  If you have any doubt as to the implications of this contact the Q&A Service Provider for further information. This document is presented for information purposes only. This document cannot and should not be used as a basis of diagnosis or choice of treatment, and is in no way intended to replace professional medical care or attention by a qualified practitioner. TRIPanswers and TRIP Database Ltd are not responsible or liable for, directly or indirectly, ANY form of damage whatsoever resulting from the use/misuse of information contained in or implied by this document.  Also, ensure you have read the terms and conditions for using the site.